Einzeltreffer — DigiBib

Background: Nasopharyngeal carcinoma (NPC) is a rare pediatric cancer. Most children are first diagnosed with advanced locoregional disease. Identification of patients at higher risk of treatment failure is crucial as they may benefit from more aggressive initial treatment approaches. 18 Fluorine-labeled fluoro-2-deoxyglucose positron emission tomography ( 18 F-FDG PET) has shown promise as a prognostic tool for predicting outcomes.

Methods: Retrospective study of pediatric patients with locally advanced undifferentiated NPC who underwent 18 F-FDG PET/CT prior to intial treatment. Predictive significance of metabolic PET parameters on survival outcomes were estimated.

Results: Thirty-two children were included, age range was 7.1-18 years at the time of diagnosis. The median follow-up duration was 46.1 months. Three patients (9.4%) were classified as AJCC stage IIb, 13 patients (40.6%) as stage IIIa, eight patients (25%) as stage IIIb, and eight patients (25%) as stage IVa. Our findings revealed that high whole-body metabolic tumor volume at the threshold of hepatic reference SUV mean (WB-MTV-HR) (>135 mL) was associated with significantly lower event-free survival (EFS) compared to the low WB-MTV-HR group (≤135 mL) (3-year EFS: 50% ± 18% vs. 82% ± 8%; p = .015). Additionally, the 3-year overall survival (OS) rates differed significantly between the high whole-body metabolic tumor volume at the threshold of an SUV of 2.5 isocontour (WB-MTV-2.5) group (MTV >74 mL) and the low WB-MTV-2.5 group (MTV ≤74 mL) (63% ± 18% vs. 100%; p = .021).

Conclusion: Our study suggests that WB-MTV parameters could serve as significant prognostic factors for disease progression in pediatric patients with locally advanced undifferentiated NPC. However, further prospective studies with larger sample sizes are needed to validate these findings.

Titel:	Predictive significance of pretreatment <superscript>18</superscript> F-FDG PET volumetric parameters on survival outcomes in pediatric patients with locally advanced undifferentiated nasopharyngeal carcinoma.
Autor/in / Beteiligte Person:	El-Hennawy, G ; ElMenawi, S ; Nasr Said, E ; Zekri, W ; Zaghloul, M ; Elsalam, AMA ; El-Fendy, H ; Elantably, I
Link:	Full Text Finder (Volltext)
Zeitschrift:	Pediatric blood & cancer, Jg. 71 (2024-07-01), Heft 7, S. e30998
Veröffentlichung:	Hoboken, N.J. : John Wiley, c 2004-, 2024
Medientyp:	academicJournal
ISSN:	1545-5017 (electronic)
DOI:	10.1002/pbc.30998
Schlagwort:	Humans Child Male Female Adolescent Retrospective Studies Prognosis Positron Emission Tomography Computed Tomography methods Survival Rate Follow-Up Studies Tumor Burden Fluorodeoxyglucose F18 Nasopharyngeal Carcinoma mortality Nasopharyngeal Carcinoma diagnostic imaging Nasopharyngeal Carcinoma pathology Nasopharyngeal Carcinoma therapy Radiopharmaceuticals Nasopharyngeal Neoplasms mortality Nasopharyngeal Neoplasms diagnostic imaging Nasopharyngeal Neoplasms pathology Nasopharyngeal Neoplasms therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Pediatr Blood Cancer] 2024 Jul; Vol. 71 (7), pp. e30998. <i>Date of Electronic Publication: </i>2024 Apr 22. MeSH Terms: Fluorodeoxyglucose F18* ; Nasopharyngeal Carcinoma* / mortality ; Nasopharyngeal Carcinoma* / diagnostic imaging ; Nasopharyngeal Carcinoma* / pathology ; Nasopharyngeal Carcinoma* / therapy ; Radiopharmaceuticals* ; Nasopharyngeal Neoplasms* / mortality ; Nasopharyngeal Neoplasms* / diagnostic imaging ; Nasopharyngeal Neoplasms* / pathology ; Nasopharyngeal Neoplasms* / therapy ; Humans ; Child ; Male ; Female ; Adolescent ; Retrospective Studies ; Prognosis ; Positron Emission Tomography Computed Tomography / methods ; Survival Rate ; Follow-Up Studies ; Tumor Burden References: Dourthe M‐E, Bolle S, Temam S, et al. Childhood nasopharyngeal carcinoma: state‐of‐the‐art, and questions for the future. J Pediatr Hematol Oncol. 2018;40(2):85‐92. ; Claude L, Jouglar E, Duverge L, Orbach D. Update in pediatric nasopharyngeal undifferentiated carcinoma. Br J Radiol. 2019;92(1102):20190107. ; Qiu W‐Z, Peng X‐S, Xia H‐Q, Huang P‐Y, Guo X, Cao K‐J. A retrospective study comparing the outcomes and toxicities of intensity‐modulated radiotherapy versus two‐dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2017;143:1563‐1572. doi:10.1007/s00432‐017‐2401‐y. ; Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003;4:13‐21. ; Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. Springer; 2017. ; Dawson CW, Port RJ, Young LS. The role of the EBV‐encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 2012;22(2):144‐153. ; Orbach D, Brisse H, Helfre S, et al. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: radiotherapy dose adaptation after chemotherapy response to minimize late effects. Pediatr Blood Cancer. 2008;50(4):849‐853. ; Jouin A, Helfre S, Bolle S, et al. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience. Strahlenther Onkol. 2019;195(6):504‐516. ; Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet. 2016;387:1012‐1024. ; Sultan I, Casanova M, Ferrari A, Rihani R, Rodriguez‐Galindo C. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer. 2010;55:279‐284. ; Rodriguez‐Galindo C, Wofford M, Castleberry RP, et al. Preradiation chemotherapy with methotrexate, cisplatin, 5‐fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer. 2005;103(4):850‐857. ; Mertens R, Granzen B, Lassay L, et al. Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC‐91‐GPOH). Cancer. 2005;104(5):1083‐1089. ; Buehrlen M, Zwaan CM, Granzen B, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC‐2003‐GPOH/DCOG. Cancer. 2012;118(19):4892‐4900. ; Casanova M, Bisogno G, Gandola L, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. Cancer. 2012;118(10):2718‐2725. ; Cheuk DKL, Billups CA, Martin MG, et al. Prognostic factors and long‐term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011;117(1):197‐206. ; Xiao W, Xu A, Han F, et al. Positron emission tomography computed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity‐modulated radiotherapy treatment: a prospective study with long‐term follow‐up. Oral Oncol. 2015;51:363‐369. ; Chang KP, Tsang NM, Liao CT, et al. Prognostic significance of 18F‐FDG PET parameters and plasma Epstein–Barr virus DNA load in patients with nasopharyngeal carcinoma. J Nucl Med. 2012;53:21‐28. ; Moon SH, Choi JY, Lee HJ, et al. Prognostic value of volume‐based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Clin Exp Otorhinolaryngol. 2015;8:142‐148. ; Rodriguez‐Galindo C, Krailo MD, Krasin MJ, et al. Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: results of the Children's Oncology Group ARAR0331 study. J Clin Oncol. 2019;37(35):3369‐3376. doi:10.1200/JCO.19.01276. ; Yu DF, Zuo CT, Dai JZ, et al. Application of 18F‐FDG PET/CT scan in following‐up of nasopharyngeal carcinoma after radiotherapy. Ai Zheng. 2004;23:1538‐1541. ; Wu DH, Chen LH. Clinical value of 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography in detecting recurrent nasopharyngeal carcinoma at the parapharyngeal space after radiotherapy. Di Yi Jun Yi Da Xue Xue Bao. 2003;23:159‐161. ; Cheuk DK, Sabin ND, Hossain M, et al. PET/CT for staging and follow‐up of pediatric nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2012;39(7):1097‐1106. doi:10.1007/s00259‐012‐2091‐2. ; Lin J, Xie G, Liao G, et al. Prognostic value of 18F‐FDG‐PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta‐analysis. Oncotarget. 2017;8(20):33884‐33896. doi:10.18632/oncotarget.13934. ; Kassambara A, Kosinski M, Biecek P. survminer: Drawing survival curves using 'ggplot2'. R package version 0.4.9. R Project; 2021. Accessed April 14, 2024. https://CRAN.R‐project.org/package=survminer. ; Hothorn T. maxstat: Maximally selected rank statistics. R package version 0.7‐25. R Project; 2017. Accessed April 14, 2024. https://CRAN.R‐project.org/package=maxstat. ; Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies. 2nd ed. Blackwell Science; 1997. ; Lee JW, Kang CM, Choi HJ, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F‐FDG PET/CT in patients with pancreatic cancer. J Nucl Med. 2014;55:898‐904. ; Ryu IS, Kim JS, Roh JL, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F‐FDG PET/CT in salivary gland carcinomas. J Nucl Med. 2013;54:1032‐1038. ; Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, Wang HM. The role of 18F‐FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2013;49:71‐78. ; Yang Z, Shi Q, Zhang Y, et al. Pretreatment (18)F‐FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma—a retrospective study. Radiat Oncol. 2015;10:4. ; Yoon HI, Kim KH, Lee J, et al. The clinical usefulness of (18)F‐fluorodeoxyglucose positron emission tomography (PET) to predict oncologic outcomes and PET‐based radiotherapeutic considerations in locally advanced nasopharyngeal carcinoma. Cancer Res Treat. 2016;48:928‐941. ; Yoon YH, Lee SH, Hong SL, Kim SJ, Roh HJ, Cho KS. Prognostic value of metabolic tumor volume as measured by fluorine‐18‐fluorodeoxyglucose positron emission tomography/computed tomography in nasopharyngeal carcinoma. Int Forum Allergy Rhinol. 2014;4:845‐850. ; Cao Y, Zhou K, Diao W, et al. Age‐related changes of standardized uptake values in the blood pool and liver: a decade‐long retrospective study of the outcomes of 2,526 subjects. Quant Imaging Med Surg. 2021;11(1):95‐106. doi:10.21037/qims‐20‐35. ; Chan SC, Chang JT, Wang HM, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol. 2009;45:52‐58. ; Lee SW, Nam SY, Im KC, et al. Prediction of prognosis using standardized uptake value of 2‐[18F] fluoro‐2‐deoxy‐dglucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol. 2008;87:211‐216. ; Chan SC, Chang JT, Lin CY, et al. Clinical utility of 18F‐FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun. 2011;32:989‐996. ; Xie P, Yue JB, Fu Z, Feng R, Yu JM. Prognostic value of 18F‐FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol. 2010;21:1078‐1082. ; Zaghloul HA, Khedr GA, Rostom Y, Refaat T. The predictive value of pretreatment 18F‐FDG‐PET‐CT in locally advanced nasopharyngeal cancer patients treated definitively with induction chemotherapy followed by concurrent chemo‐radiotherapy. J Nucl Med Radiat Ther. 2014;5(1):166. ; Zhang Y, Li WF, Mao YP, et al. Establishment of an integrated model incorporating standardised uptake value and N‐classification for predicting metastasis in nasopharyngeal carcinoma. Oncotarget. 2016;7:13612‐13620. doi:10.18632/oncotarget.7253. ; Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43‐46. ; Althouse AD. Adjust for multiple comparisons? It's not that simple. Ann Thorac Surg. 2016;101(5):1644‐1645. doi:10.1016/j.athoracsur.2015.11.024. Contributed Indexing: Keywords: 18F‐FDG PET/CT; locally advanced; metabolic parameters; pediatric; pretreatment; undifferentiated nasopharyngeal carcinoma Substance Nomenclature: 0Z5B2CJX4D (Fluorodeoxyglucose F18) ; 0 (Radiopharmaceuticals) Entry Date(s): Date Created: 20240423 Date Completed: 20240523 Latest Revision: 20240523 Update Code: 20240523

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Predictive significance of pretreatment <superscript>18</superscript> F-FDG PET volumetric parameters on survival outcomes in pediatric patients with locally advanced undifferentiated nasopharyngeal carcinoma.